Celldex Therapeutics (CLDX) Profit After Tax (2010 - 2026)
Celldex Therapeutics (CLDX) posted quarterly Profit After Tax of -$79.8 million for Q1 2026, down 48.32% year-over-year from -$154.4 million in Q1 2025, and up 2.42% quarter-over-quarter from -$81.8 million in Q4 2025.
Celldex Therapeutics (CLDX) Profit After Tax (2010 - 2026) Analysis & Trends
Celldex Therapeutics' Profit After Tax history runs 17 years deep, the most recent figure standing at -$79.8 million for Q1 2026.
- In Q1 2026, Profit After Tax fell 48.32% year-over-year to -$79.8 million; the TTM figure through Mar 2026 stood at -$285.2 million (down 59.47% YoY), while the FY2025 annual figure was -$258.8 million, down 63.92% from the prior year.
- Profit After Tax for Q1 2026 stood at -$79.8 million, up from -$81.8 million in the prior quarter.
- The five-year high for Profit After Tax was -$24.8 million in Q1 2022, with the low at -$81.8 million in Q4 2025.
- The 5-year median for Profit After Tax is -$38.2 million (2023), against an average of -$44.1 million.
- The sharpest annual moves came in 2022 and 2023: Profit After Tax slumped 173.29% in 2022, then increased 16.37% in 2023.
- Celldex Therapeutics' Profit After Tax stood at -$25.1 million in 2022, then slumped by 67.76% to -$42.1 million in 2023, then decreased by 11.76% to -$47.1 million in 2024, then sank by 73.66% to -$81.8 million in 2025, then rose by 2.42% to -$79.8 million in 2026.
- Business Quant data shows CLDX's Profit After Tax at -$79.8 million in Q1 2026, -$81.8 million in Q4 2025, and -$67.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 472.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,087.27 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -16.62 Mn |
| 10 | Celldex Therapeutics | 3.29 Bn | 2.58 Bn | -2.57 Mn | -74.73 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -74.73 Mn |
| Mar 31, 2026 | -79.79 Mn |
| Dec 31, 2025 | -81.77 Mn |
| Sep 30, 2025 | -67.04 Mn |
| Jun 30, 2025 | -56.60 Mn |
| Mar 31, 2025 | -53.80 Mn |
| Dec 31, 2024 | -47.09 Mn |
| Sep 30, 2024 | -42.12 Mn |
| Jun 30, 2024 | -35.84 Mn |
| Mar 31, 2024 | -32.81 Mn |
| Dec 31, 2023 | -42.13 Mn |
| Sep 30, 2023 | -38.20 Mn |
| Jun 30, 2023 | -30.55 Mn |
| Mar 31, 2023 | -28.50 Mn |
| Dec 31, 2022 | -25.12 Mn |
| Sep 30, 2022 | -26.48 Mn |
| Jun 30, 2022 | -36.53 Mn |
| Mar 31, 2022 | -24.83 Mn |
| Dec 31, 2021 | -20.80 Mn |
| Sep 30, 2021 | -20.50 Mn |